Literature DB >> 3106105

Outcome of in vitro fertilization in women with low response to ovarian stimulation.

A Pellicer, A Lightman, M P Diamond, J B Russell, A H DeCherney.   

Abstract

The occurrence of low-response (LR) cycles (defined as peak estradiol levels less than 300 pg/ml) in an in vitro fertilization program using a 3 ampule/day human menopausal gonadotropin regimen were retrospectively reviewed. LR occurred in 51 of 564 patients (9%). The LR serum estradiol levels were categorized into four different patterns that were further analyzed for outcome in these initial cycles, as well as for their predictive value of response in subsequent in vitro fertilization cycles. Changing the stimulation protocol to a combination of clomiphene citrate and human menopausal gonadotropin did not improve the ovarian response in this group of LR patients, and their chance to complete a subsequent normal-response treatment cycle was 32%. Suggestions are made to predict outcome and govern management of women with previous LR cycles.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106105     DOI: 10.1016/s0015-0282(16)59170-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  20 in total

1.  Conversion from assisted reproductive technology to intrauterine insemination in low responders: is it advantageous?

Authors:  John M Norian; Eric D Levens; Kevin S Richter; Eric A Widra; Michael J Levy
Journal:  Fertil Steril       Date:  2010-02-19       Impact factor: 7.329

2.  Cost-effectiveness analysis comparing continuation of assisted reproductive technology with conversion to intrauterine insemination in patients with low follicle numbers.

Authors:  Bo Yu; Sunni Mumford; G Donald Royster; James Segars; Alicia Y Armstrong
Journal:  Fertil Steril       Date:  2014-06-18       Impact factor: 7.329

3.  Effect of follicular flushing on reproductive outcomes in patients with poor ovarian response undergoing assisted reproductive technology.

Authors:  Anna L M Souza; Marcos Sampaio; Graciele B Noronha; Ludiana G R Coster; Roberta S G de Oliveira; Selmo Geber
Journal:  J Assist Reprod Genet       Date:  2017-07-21       Impact factor: 3.412

4.  Endocrine disruptive actions of inhaled benzo(a)pyrene on ovarian function and fetal survival in fisher F-344 adult rats.

Authors:  Anthony E Archibong; Aramandla Ramesh; Frank Inyang; Mohammad S Niaz; Darryl B Hood; Prapaporn Kopsombut
Journal:  Reprod Toxicol       Date:  2012-10-08       Impact factor: 3.143

5.  Antral follicle assessment as a tool for predicting outcome in IVF--is it a better predictor than age and FSH?

Authors:  R Nahum; J L Shifren; Y Chang; L Leykin; K Isaacson; T L Toth
Journal:  J Assist Reprod Genet       Date:  2001-03       Impact factor: 3.412

6.  The poor-responder patient in an in vitro fertilization-embryo transfer program.

Authors:  Z Ben-Rafael; D Feldberg
Journal:  J Assist Reprod Genet       Date:  1993-02       Impact factor: 3.412

7.  The potential use of maturation in vitro of human oocytes in low responder patients.

Authors:  A Requena; F Neuspiller; A C Cobo; M Aragonés; J Remohí; C Simón; A Pellicer
Journal:  J Assist Reprod Genet       Date:  2000-05       Impact factor: 3.412

8.  Urinary bisphenol A concentrations and ovarian response among women undergoing IVF.

Authors:  E Mok-Lin; S Ehrlich; P L Williams; J Petrozza; D L Wright; A M Calafat; X Ye; R Hauser
Journal:  Int J Androl       Date:  2009-11-30

9.  Follicle stimulating hormone levels on cycle day 3 predict ovulation stimulation response.

Authors:  A Ebrahim; G Rienhardt; S Morris; T F Kruger; C J Lombard; J P Van der Merwe
Journal:  J Assist Reprod Genet       Date:  1993-02       Impact factor: 3.412

10.  Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF.

Authors:  Sozos J Fasouliotis; Neri Laufer; Shelley Sabbagh-Ehrlich; Aby Lewin; Arye Hurwitz; Alex Simon
Journal:  J Assist Reprod Genet       Date:  2003-11       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.